Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough Pharmaceutical Investing
FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11 Cannabis Investing News
Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110 Percent Biotech Investing
Harvest One Signs Supply Agreement with the Alberta Gaming, Liquor & Cannabis Commission Cannabis Investing News
